Grünenthal Prices €850 Million Bond Offering With Fixed- and Floating-Rate Tranches

Grünenthal has priced €850 million of senior secured notes due 2032, splitting the financing between a fixed-rate tranche and a larger floating-rate tranche as the German pharmaceutical company moves to push out debt maturities and preserve capital for strategic spending.

The Aachen-based group said €400 million will carry a fixed coupon of 5.375%, while €450 million will pay Euribor plus 275 basis points. Both tranches are due in 2032 and will be issued at 100% of face value. Grünenthal plans to use the proceeds to redeem most of its outstanding notes due 2028 and all of its outstanding 2030 notes, with additional funds available for strategic initiatives.

Two tranches share a 2032 maturity

According to the pricing announcement distributed through Deutsche Börse, the fixed-rate portion totals €400 million at 5.375%. The €450 million floating-rate portion is priced at 275 basis points above Euribor. Both pieces mature in 2032, giving Grünenthal a single maturity year for the newly issued debt even though the interest-rate mechanics differ.

The split leaves Grünenthal with two kinds of funding cost. The coupon on the fixed-rate notes is set for the life of that tranche, while the floating-rate notes will move with the relevant Euribor benchmark plus the stated 2.75 percentage-point spread. The company did not give a single all-in coupon for the floating tranche in its announcement, so its future interest cost will depend on Euribor over time.

Both tranches are being issued at par. Grünenthal said the notes were offered outside the United States under Regulation S and, in the United States, only to qualified institutional buyers under Rule 144A. Fitch Ratings assigned a BB+ rating, S&P assigned BB-, and Moody’s Investors Service assigned Ba3, according to the company announcement.

The financing is secured and ranks as part of Grünenthal’s creditor capital structure rather than equity financing. That distinction matters because the proceeds are primarily being used to replace existing debt rather than fund a stand-alone expansion project. The company has not disclosed in the pricing announcement how much of the €850 million will remain after the planned redemptions and related costs for other strategic uses.

Refinancing clears 2030 debt and most 2028 notes

The planned use of proceeds puts refinancing at the center of the deal. Grünenthal intends to redeem the majority of its notes due in 2028 and all of the notes due in 2030, shifting a meaningful portion of those obligations into debt that matures in 2032. Its existing senior secured notes due in 2031 will remain unchanged.

That 2031 debt was expanded less than a year ago. In November 2025, Grünenthal increased the issue by €175 million to €675 million, keeping the 4.625% interest rate and 2031 maturity. The company said at the time that proceeds from that extension would be used to reduce bank liabilities and for general corporate purposes, including possible add-on acquisitions and payments tied to existing joint-venture arrangements.

The new 2032 notes therefore continue a broader effort to reshape Grünenthal’s maturity profile. Chief Financial Officer Fabian Raschke said the company is seeking to extend maturities and increase financial flexibility. Chief Executive Officer Gabriel Baertschi linked the financing to Grünenthal’s ability to continue advancing its research pipeline and pursue strategic acquisitions.

Because much of the new cash is earmarked for retiring existing notes, the €850 million face value should not be read as an €850 million increase in net debt. The eventual balance-sheet effect will depend on the amount paid to redeem the older securities, financing costs, cash retained for strategic initiatives and other funding movements. Grünenthal did not provide a pro forma net-debt figure in the pricing announcement.

Cash generation gives the refinancing more context

Grünenthal enters the refinancing after a year of stronger profitability and cash generation. In its 2025 financial results, the company reported revenue of €1.8 billion and record adjusted EBITDA of €500 million, up more than 20% from 2024. Operating cash flow rose 46% to €309 million, while year-end net leverage was 2.24 times.

The latest bond announcement also points to the longer-term change in the business. Grünenthal said adjusted EBITDA has risen from €129 million in 2017 to €500 million in 2025. Over that period, it has expanded through both organic growth and acquisitions, changing its product and therapeutic-area mix while increasing profitability.

Those figures help explain why the company is addressing upcoming maturities before they become near-term deadlines. Replacing a large portion of 2028 and 2030 debt with 2032 notes can reduce the concentration of refinancing needs in the next several years, although it also introduces a sizable floating-rate exposure through the €450 million Euribor-linked tranche.

The fixed and floating structure also means future financing costs will not move uniformly. Grünenthal knows the 5.375% coupon on the fixed portion, but the cost of the floating tranche can rise or fall as Euribor changes. The 275-basis-point spread remains the contractual margin above that benchmark.

Grünenthal expects the offering to close on September 29, 2026. Until settlement, the notes have been priced but the issuance has not yet completed. The closing will be the next concrete step in the refinancing plan, after which the company can proceed with the stated redemptions of its 2028 and 2030 notes.